Modified Zn-MOF multifunctional nanoparticles for combination therapy of DN and exploratory study of the

Yuna Tong1, Xiuxiu Li2, Yuxuan Zhu3

  • 1Department of Nephrology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China; Department of Nephrology, The Third People's Hospital of Chengdu, Chengdu 610031, China.

Insights

This study developed novel metformin-encapsulated zinc-based nanoparticles (KTP-Zn-MOF/MET) for targeted diabetic nephropathy (DN) treatment. The nanoparticles effectively reduced kidney damage and oxidative stress in animal models, showing promise for clinical application.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Nephrology

Background:

  • Diabetic nephropathy (DN) pathogenesis involves hyperglycemia, oxidative stress, and inflammation, with current treatments limited by complex pathways.
  • Zinc (Zn) is vital for physiological processes, offering protection against oxidative stress and playing a role in insulin regulation.

Purpose of the Study:

  • To engineer multifunctional nanoparticles for targeted intervention in diabetic nephropathy (DN).
  • To develop metformin (MET)-encapsulated zinc-based metal-organic framework (Zn-MOF) nanoparticles conjugated with a renal-targeting protein (KTP-Zn-MOF/MET).

Main Methods:

  • In vivo imaging in BALB/c nude mice to assess renal accumulation of KTP-Zn-MOF/MET.
  • Evaluation of nephroprotective efficacy in a streptozotocin-induced rat model of renal injury.

Main Results:

  • KTP-Zn-MOF/MET demonstrated significantly enhanced renal accumulation in mice.
  • Intravenous administration of KTP-Zn-MOF/MET ameliorated renal functional impairment, apoptosis, lipid peroxidation, and oxidative stress in rats.

Conclusions:

  • KTP-Zn-MOF/MET represents a novel therapeutic strategy for precise renal targeting and multi-target intervention in DN.
  • This approach holds significant potential for clinical translation in managing diabetic nephropathy.